Oseltamivir prophylaxis for the prevention of influenza in healthy healthcare workers: Tolerability and compliance challenges

Branch‐Elliman, Westyn; Yassa, David S.; Wright, Sharon B.

doi:10.1017/ice.2019.232

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oseltamivir is the most common neuraminidase inhibitors, and is widely used in Japan. Oseltamivir usually requires a five-day oral treatment regimen, although non-compliance to the drug is a major concern for reduced efficacy and emergence of resistant strains [ 5 – 7 ]. Laninamivir is a long-acting neuraminidase inhibitors, and is administered by nasal inhalation as a single dose.…”

Section: Introductionmentioning

confidence: 99%

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan

Fujiwara

Fujiwara²,

Ise

2023

J Pharm Health Care Sci

View full text Add to dashboard Cite

Background We aimed to evaluate the factors associated with baloxavir prescription in Japanese hospitals using a health insurance claim-based database (MDV analyzer), during the 2018/2019 and 2019/2020 influenza seasons. The MDV analyzer contains anonymized claims data from approximately 420 Diagnosis Procedure Combination hospitals, and does not contain data from clinics. Methods Data were collected for influenza patients treated with anti-influenza drugs during the 2018/2019 and 2019/2020 influenza seasons. Multivariate analysis was used to identify factors associated with baloxavir prescription. Results During the study period, 322,063 influenza patients were included for analyses. In multivariate analysis, children, female sex, inpatient, hospital bed capacity, and private hospitals were negatively associated with baloxavir prescription. Compared to elderly patients, the adjusted odds ratio (OR) for baloxavir prescription was 0.612 (95% confidence interval (CI), 0.587–0.637) in children aged 6–11 years, and 0.119 (95% CI, 0.111–0.128) in children aged 0–5 years. Compared to small hospitals (bed capacity, 20–299), the adjusted OR for baloxavir prescription was 0.559 (95% CI, 0.540–0.578) in large hospitals (bed capacity, ≥ 500). Conclusion Children, female sex, inpatient, hospital bed capacity, and private hospitals were negatively associated with baloxavir prescription.

show abstract

Section: Introductionmentioning

confidence: 99%

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan

Fujiwara

Fujiwara²,

Ise

2023

J Pharm Health Care Sci

View full text Add to dashboard Cite

show abstract

Modeling the Impacts of Antiviral Prophylaxis Strategies in Mitigating Seasonal Influenza Outbreaks in Nursing Homes

Morris,

Zipfel,

Peer

et al. 2023

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Antiviral chemoprophylaxis is recommended for use during influenza outbreaks in nursing homes to prevent transmission and severe disease among non-ill residents. Centers for Disease Control and Prevention (CDC) guidance recommends prophylaxis be initiated for all non-ill residents once an influenza outbreak is detected and be continued for at least 14 days and until seven days after the last laboratory-confirmed influenza case is identified. However, not all facilities strictly adhere to this guidance and the impact of such partial adherence is not fully understood. Methods We developed a stochastic compartmental framework to model influenza transmission within an average-sized U.S. nursing home. We compared the number of symptomatic illnesses and hospitalizations under varying prophylaxis implementation strategies, in addition to different levels of prophylaxis uptake and adherence by residents and healthcare personnel (HCP). Results Prophylaxis implemented according to current guidance reduced total symptomatic illnesses and hospitalizations among residents by an average of 12% and 36%, respectively, compared with no prophylaxis. We did not find evidence that alternative implementations of prophylaxis were more effective: compared to full adoption of current guidance, partial adoption resulted in increased symptomatic illnesses and/or hospitalizations, and longer or earlier adoption offered no additional improvements. In addition, increasing uptake and adherence among nursing home residents was effective in reducing resident illnesses and hospitalizations, but increasing HCP uptake had minimal indirect impacts for residents. Conclusions The greatest benefits of influenza prophylaxis during nursing home outbreaks will likely be achieved through increasing uptake and adherence among residents and following current CDC guidance.

show abstract

Oseltamivir prophylaxis for the prevention of influenza in healthy healthcare workers: Tolerability and compliance challenges

Cited by 2 publications

References 8 publications

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan

Modeling the Impacts of Antiviral Prophylaxis Strategies in Mitigating Seasonal Influenza Outbreaks in Nursing Homes

Contact Info

Product

Resources

About